Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Cash from Investing Activities (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Cash from Investing Activities for 7 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 95.48% to $1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $134.3 million, a 4.31% decrease, with the full-year FY2025 number at $134.3 million, down 4.31% from a year prior.
  • Cash from Investing Activities was $1.8 million for Q4 2025 at Pliant Therapeutics, down from $27.9 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $69.1 million in Q1 2025 to a low of -$178.3 million in Q3 2022.
  • A 5-year average of $3.6 million and a median of $22.9 million in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 11478.71% in 2023, then soared 231.59% in 2025.
  • Pliant Therapeutics' Cash from Investing Activities stood at $25.8 million in 2021, then decreased by 22.34% to $20.0 million in 2022, then soared by 59.43% to $31.9 million in 2023, then grew by 22.59% to $39.1 million in 2024, then plummeted by 95.48% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Cash from Investing Activities are $1.8 million (Q4 2025), $27.9 million (Q3 2025), and $35.5 million (Q2 2025).